TY - JOUR
T1 - Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy
AU - Kataoka, Yu
AU - Puri, Rishi
AU - Hammadah, Muhammad
AU - Duggal, Bhanu
AU - Uno, Kiyoko
AU - Kapadia, Samir R.
AU - Tuzcu, E. Murat
AU - Nissen, Steven E.
AU - Nicholls, Stephen J.
N1 - Funding Information:
Dr. Nicholls has received speaking honoraria from AstraZeneca , USA, Pfizer , USA, Merck, USA, Schering-Plough , USA, and Takeda Pharmaceuticals International, Inc , USA; consulting fees from AstraZeneca , USA, Pfizer , USA, Merck, USA, Schering-Plough , USA, Takeda Pharmaceuticals International, Inc , USA, Roche , Switzerland, Novo Nordisk , Denmark, LipoScience , USA, and Anthera , USA; and research support from AstraZeneca , USA and Lipid Sciences, Inc , USA.
PY - 2014/8/15
Y1 - 2014/8/15
N2 - Potent statin therapy has been demonstrated to reduce cardiovascular events. Although statins have been considered to stabilize atherosclerotic plaque, this effect has not been well characterized in vivo. We investigated the relation between potent statin therapy and plaque microstructures imaged by frequency-domain optical coherence tomography. Two hundred ninety nonculprit lipid plaques in 275 patients with stable coronary artery disease receiving atorvastatin or rosuvastatin were analyzed. Patients were stratified into no statin, low-, and high-dose statin groups. Plaques in the high-dose statin group demonstrated a smaller lipid arc (p = 0.02) and a greater fibrous cap thickness (p = 0.01). In patients receiving statin therapy, high-dose statin therapy was associated with a greater fibrous cap thickness in patients with smaller (148.2 ± 30.5 vs 105.3 ± 41.1 μm, p = 0.004) but not larger lipid index (91.1 ± 32.6 vs 78.1 ± 43.3 μm, p = 0.21). In conclusion, potent statin therapy is associated with less vulnerable plaque features on frequency-domain optical coherence tomography imaging. This finding varies according to the size of plaque lipid content, being less effective in lipid-loaded plaques.
AB - Potent statin therapy has been demonstrated to reduce cardiovascular events. Although statins have been considered to stabilize atherosclerotic plaque, this effect has not been well characterized in vivo. We investigated the relation between potent statin therapy and plaque microstructures imaged by frequency-domain optical coherence tomography. Two hundred ninety nonculprit lipid plaques in 275 patients with stable coronary artery disease receiving atorvastatin or rosuvastatin were analyzed. Patients were stratified into no statin, low-, and high-dose statin groups. Plaques in the high-dose statin group demonstrated a smaller lipid arc (p = 0.02) and a greater fibrous cap thickness (p = 0.01). In patients receiving statin therapy, high-dose statin therapy was associated with a greater fibrous cap thickness in patients with smaller (148.2 ± 30.5 vs 105.3 ± 41.1 μm, p = 0.004) but not larger lipid index (91.1 ± 32.6 vs 78.1 ± 43.3 μm, p = 0.21). In conclusion, potent statin therapy is associated with less vulnerable plaque features on frequency-domain optical coherence tomography imaging. This finding varies according to the size of plaque lipid content, being less effective in lipid-loaded plaques.
UR - https://www.scopus.com/pages/publications/84905571707
UR - https://www.scopus.com/pages/publications/84905571707#tab=citedBy
U2 - 10.1016/j.amjcard.2014.05.035
DO - 10.1016/j.amjcard.2014.05.035
M3 - Article
C2 - 24996554
AN - SCOPUS:84905571707
SN - 0002-9149
VL - 114
SP - 549
EP - 554
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 4
ER -